analysts at Cantor Fitzgerald said it does not affect Biohaven’s valuation, which is more closely tied to oral CGRP inhibitor drug rimegepant in late-stage for acute migraine treatment ...

The charges allege that Biohaven submitted false claims to Medicare ... so they would preferentially prescribe the company’s migraine drug Nurtec ODT (rimegepant). A kickback is a negotiated ...

Pfizer (NYSE:PFE) has agreed to pay nearly $60M to resolve allegations that its Biohaven unit paid kickbacks to physicians to induce prescriptions for its migraine drug Nurtec ODT. The U.S ...

Four Colorado physicians are named in a lawsuit settlement involving pharmaceutical company Biohaven, which allegedly paid ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. The registrational study assessed BHV-7000, a drug designed to selectively activate Kv7.2/Kv7.3 ...

Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking the company’s stock price. The US-based biotech shared the ...

Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs by paying kickbacks so doctors would prescribe the migraine drug Nurtec ...

Biohaven previously received both Fast-Track and Orphan Drug Designation (ODD ... TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders ...

Biohaven's antibody drug conjugate (ADC ... advancing enrollment in proof of concept trial with BHV-2100 in acute migraine; data from the laser-evoked potential study expected in 1H 2025.